SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Merck Updates BELLWAVE Clinical Development Program

Merck announced an update on its BELLWAVE clinical development program evaluating nemtabrutinib.

MRK

Related stories